RAPT Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- RAPT Therapeutics's estimated annual revenue is currently $23.4M per year.
- RAPT Therapeutics's estimated revenue per employee is $131,489
- RAPT Therapeutics's total funding is $319.7M.
Employee Data
- RAPT Therapeutics has 178 Employees.
- RAPT Therapeutics grew their employee count by 11% last year.
RAPT Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President and CEO | Reveal Email/Phone |
2 | VP Clinical Operations | Reveal Email/Phone |
3 | VP, Clinical Development | Reveal Email/Phone |
4 | VP, Business Development and Strategy | Reveal Email/Phone |
5 | VP Commercial | Reveal Email/Phone |
6 | SVP Regulatory Affairs and Quality Assurance | Reveal Email/Phone |
7 | Associate Director | Reveal Email/Phone |
8 | Associate Director, Analytical Development | Reveal Email/Phone |
9 | Director Information Technology | Reveal Email/Phone |
10 | Chief Scientific Officer | Reveal Email/Phone |
RAPT Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is RAPT Therapeutics?
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company develops highly selective small molecules that are designed to modulate the fundamental immune responses underlying these diseases. RAPT has rapidly discovered and advanced two unique drug candidates each targeting CCR4, including our lead oncology drug candidate, FLX475, now in clinical development and our lead inflammation drug candidate, RPT193, expected to enter the clinic in the second half of 2019. The company is also pursuing other discovery targets including GCN2 and HPK1 for the treatment of cancer.
keywords:saas
$319.7M
Total Funding
178
Number of Employees
$23.4M
Revenue (est)
11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
RAPT Therapeutics News
Loss-making RAPT Therapeutics (NASDAQ:RAPT) sheds a further US$54m, taking total shareholder losses to 13% over 1 year. By: Simply Wall St.
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Insider Dirk G. Brockstedt Sells 2,647 Shares. Posted by admin on Apr 13th, 2022.
SOUTH SAN FRANCISCO, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based...
Just ten days after two co-founders of San Francisco pricing software company Rapt sued its venture backers, the case has been settled. We thought it would be quick (see our original story here), because high-profile venture firm Accel Partners, and another valley firm, Levensohn Venture Partne ...
Two co-founders of Rapt have sued the company’s chief executive and venture capital backers, Accel Partners and Levensohn Venture Partners for breach of fiduciary duty and fraud. Rapt is a San Francisco company that provides software to help companies find the right price for their goods to max ...
Other Companies in South San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $27.6M | 178 | 6% | N/A |
#2 | $37.2M | 192 | -7% | $92.1M |
#3 | $179.9M | 197 | -60% | $532.5M |
#4 | $31.5M | 203 | 1% | N/A |
#5 | $199.8M | 206 | 28% | $333.1M |